Status:
COMPLETED
Lung Cancer Screening Eligibility Assessment
Lead Sponsor:
Abramson Cancer Center at Penn Medicine
Collaborating Sponsors:
National Institutes of Health (NIH)
National Cancer Institute (NCI)
Conditions:
Lung Cancer
Eligibility:
All Genders
50-80 years
Phase:
NA
Brief Summary
The primary purpose of this study evaluate if different messaging impacts response rates to a brief survey (i.e., the simplified eligibility tool) that is designed to estimate pack-year eligibility fo...
Detailed Description
Despite growing evidence that lung cancer screening (LCS) reduces lung cancer-specific mortality, LCS across the United States is remarkably low. This is due in part to challenges with identifying adu...
Eligibility Criteria
Inclusion
- meet age eligibility (50-80 years old) for LCS based on 2021 USPSTF guidelines; and
- have completed at least one primary care visit at Penn Medicine in 2020-2025
Exclusion
- have a documented history of lung cancer;
- have a documented history of completing LCS at Penn Medicine;
- are listed as not wanting to be contacted or solicited for research; or
- do not otherwise meet inclusion criteria.
Key Trial Info
Start Date :
July 31 2023
Trial Type :
INTERVENTIONAL
Allocation :
ACTUAL
End Date :
January 31 2024
Estimated Enrollment :
6125 Patients enrolled
Trial Details
Trial ID
NCT06133816
Start Date
July 31 2023
End Date
January 31 2024
Last Update
May 31 2025
Active Locations (1)
Enter a location and click search to find clinical trials sorted by distance.
1
University of Pennsylvania
Philadelphia, Pennsylvania, United States, 19104